# US 2021/0277010 A1 · Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277010 A1
- Document ID: US20210277010A1
- Status: Published application
- Kind: A1
- Application number: 17/318,677
- Filed: 2021-05-12
- Published: 2021-09-09
- Earliest claimed: 2012-12-12
- Assignees: ARIAD Pharmaceuticals, Inc.
- Applicants: ARIAD Pharmaceuticals, Inc.
- Inventors: Christopher K. Murray; Leonard W. Rozamus; John J. Chaber; Pradeep K. Sharma
- Web page: https://patentgrep.com/patent/US20210277010A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.

## Claims

### Claim at position 1

1-125. (canceled)

### Claim 126

A method for treating chronic phase chronic myeloid leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one crystalline form of ponatinib hydrochloride characterized by:
a) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 5.9, 7.1, 10.0, 12.5, 13.6, 14.1, 15.0, 16.4, 17.7, 18.6, 19.3, 20.4, 21.8, 22.3, 23.8, 24.9, 26.1, 27.0, 28.4, 30.3, 31.7, and 35.1;
b) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 3.1, 6.5, 12.4, 13.8, 15.4, 16.2, 17.4, 18.0, 20.4, 23.2, 24.4, 26.1, and 26.9;
c) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 3.1, 6.5, 12.4, 13.8, 17.4, 18.0, 20.6, 22.0, 23.0, 25.5, 26.5, 27.4, 28.4, and 29.0;
d) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 8.2, 10.1, 10.9, 14.9, 16.0, 16.3, 16.8, 17.7, 18.7, 20.2, 22.9, 24.0, 25.6, 26.7, and 28.5;
e) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl1+HCl4 (GRP1.1);
f) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 7.9, 8.7, 9.7, 11.4, 15.6, 16.5, and 25.8;
g) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl5b (VDS28.2);
h) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 8.0, 10.2, 10.9, 11.8, 14.1, 15.4, 16.3, 19.9, 22.3, 23.7, 25.0, and 28.2;
i) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 6.1, 7.0, 13.3, 16.4, 20.7, 22.2, 23.9, 25.5, and 29.1; or
j) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 6.1, 7.4, 13.5, 17.4, 18.5, 20.7, 23.9, and 28.3.

### Claim 127 (depends on 126)

The method according to claim 126, wherein the subject is resistant or intolerant to at least one prior tyrosine-kinase inhibitor.

### Claim 128 (depends on 127)

The method according to claim 127, wherein the subject is resistant or intolerant to at least two prior tyrosine-kinase inhibitors.

### Claim 129 (depends on 126)

The method according to claim 126, wherein the leukemia results from a mutation in the Bcr-Abl kinase domain.

### Claim 130 (depends on 126)

The method according to claim 126, wherein the pharmaceutical composition comprises crystalline Form A of ponatinib hydrochloride.

### Claim 131 (depends on 126)

The method according to claim 126, wherein the pharmaceutical composition consists essentially of crystalline Form A of ponatinib hydrochloride.

### Claim 132

A method for treating acute phase chronic myeloid leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one crystalline form of ponatinib hydrochloride characterized by:
a) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 5.9, 7.1, 10.0, 12.5, 13.6, 14.1, 15.0, 16.4, 17.7, 18.6, 19.3, 20.4, 21.8, 22.3, 23.8, 24.9, 26.1, 27.0, 28.4, 30.3, 31.7, and 35.1;
b) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 3.1, 6.5, 12.4, 13.8, 15.4, 16.2, 17.4, 18.0, 20.4, 23.2, 24.4, 26.1, and 26.9;
c) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 3.1, 6.5, 12.4, 13.8, 17.4, 18.0, 20.6, 22.0, 23.0, 25.5, 26.5, 27.4, 28.4, and 29.0;
d) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 8.2, 10.1, 10.9, 14.9, 16.0, 16.3, 16.8, 17.7, 18.7, 20.2, 22.9, 24.0, 25.6, 26.7, and 28.5;
e) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl1+HCl4 (GRP1.1);
f) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 7.9, 8.7, 9.7, 11.4, 15.6, 16.5, and 25.8;
g) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl5b (VDS28.2);
h) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 8.0, 10.2, 10.9, 11.8, 14.1, 15.4, 16.3, 19.9, 22.3, 23.7, 25.0, and 28.2;
i) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 6.1, 7.0, 13.3, 16.4, 20.7, 22.2, 23.9, 25.5, and 29.1; or
j) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 6.1, 7.4, 13.5, 17.4, 18.5, 20.7, 23.9, and 28.3.

### Claim 133 (depends on 132)

The method according to claim 132, wherein the subject is resistant or intolerant to at least one prior tyrosine-kinase inhibitor.

### Claim 134 (depends on 133)

The method according to claim 133, wherein the subject is resistant or intolerant to at least two prior tyrosine-kinase inhibitors.

### Claim 135 (depends on 132)

The method according to claim 132, wherein the leukemia results from a mutation in the Bcr-Abl kinase domain.

### Claim 136 (depends on 132)

The method according to claim 132, wherein the pharmaceutical composition comprises crystalline Form A of ponatinib hydrochloride.

### Claim 137 (depends on 132)

The method according to claim 132, wherein the pharmaceutical composition consists essentially of crystalline Form A of ponatinib hydrochloride.

### Claim 138

A method for treating blast phase chronic myeloid leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one crystalline form of ponatinib hydrochloride characterized by:
a) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 5.9, 7.1, 10.0, 12.5, 13.6, 14.1, 15.0, 16.4, 17.7, 18.6, 19.3, 20.4, 21.8, 22.3, 23.8, 24.9, 26.1, 27.0, 28.4, 30.3, 31.7, and 35.1;
b) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 3.1, 6.5, 12.4, 13.8, 15.4, 16.2, 17.4, 18.0, 20.4, 23.2, 24.4, 26.1, and 26.9;
c) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 3.1, 6.5, 12.4, 13.8, 17.4, 18.0, 20.6, 22.0, 23.0, 25.5, 26.5, 27.4, 28.4, and 29.0;
d) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 8.2, 10.1, 10.9, 14.9, 16.0, 16.3, 16.8, 17.7, 18.7, 20.2, 22.9, 24.0, 25.6, 26.7, and 28.5;
e) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl1+HCl4 (GRP1.1);
f) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 7.9, 8.7, 9.7, 11.4, 15.6, 16.5, and 25.8;
g) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl5b (VDS28.2);
h) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 8.0, 10.2, 10.9, 11.8, 14.1, 15.4, 16.3, 19.9, 22.3, 23.7, 25.0, and 28.2;
i) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 6.1, 7.0, 13.3, 16.4, 20.7, 22.2, 23.9, 25.5, and 29.1; or
j) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 6.1, 7.4, 13.5, 17.4, 18.5, 20.7, 23.9, and 28.3.

### Claim 139 (depends on 138)

The method according to claim 138, wherein the subject is resistant or intolerant to at least one prior tyrosine-kinase inhibitor.

### Claim 140 (depends on 139)

The method according to claim 139, wherein the subject is resistant or intolerant to at least two prior tyrosine-kinase inhibitors.

### Claim 141 (depends on 138)

The method according to claim 138, wherein the leukemia results from a mutation in the Bcr-Abl kinase domain.

### Claim 142 (depends on 138)

The method according to claim 138, wherein the pharmaceutical composition comprises crystalline Form A of ponatinib hydrochloride.

### Claim 143 (depends on 138)

The method according to claim 138, wherein the pharmaceutical composition consists essentially of crystalline Form A of ponatinib hydrochloride.

### Claim 144

A method for treating Philadelphia chromosome positive acute lymphoblastic leukemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising at least one crystalline form of ponatinib hydrochloride characterized by:
a) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 5.9, 7.1, 10.0, 12.5, 13.6, 14.1, 15.0, 16.4, 17.7, 18.6, 19.3, 20.4, 21.8, 22.3, 23.8, 24.9, 26.1, 27.0, 28.4, 30.3, 31.7, and 35.1;
b) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 3.1, 6.5, 12.4, 13.8, 15.4, 16.2, 17.4, 18.0, 20.4, 23.2, 24.4, 26.1, and 26.9;
c) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 3.1, 6.5, 12.4, 13.8, 17.4, 18.0, 20.6, 22.0, 23.0, 25.5, 26.5, 27.4, 28.4, and 29.0;
d) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 8.2, 10.1, 10.9, 14.9, 16.0, 16.3, 16.8, 17.7, 18.7, 20.2, 22.9, 24.0, 25.6, 26.7, and 28.5;
e) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl1+HCl4 (GRP1.1);
f) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 7.9, 8.7, 9.7, 11.4, 15.6, 16.5, and 25.8;
g) an x-ray powder diffraction pattern substantially as shown in FIG. 41 labelled HCl5b (VDS28.2);
h) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 8.0, 10.2, 10.9, 11.8, 14.1, 15.4, 16.3, 19.9, 22.3, 23.7, 25.0, and 28.2;
i) an x-ray powder diffraction pattern comprising at least three 2θ values (±0.3) chosen from 6.1, 7.0, 13.3, 16.4, 20.7, 22.2, 23.9, 25.5, and 29.1; or
j) an x-ray powder diffraction pattern comprising at least three 2θ values (+0.3) chosen from 6.1, 7.4, 13.5, 17.4, 18.5, 20.7, 23.9, and 28.3.

### Claim 145 (depends on 144)

The method according to claim 144, wherein the subject is resistant or intolerant to at least one prior tyrosine-kinase inhibitor.

### Claim 146 (depends on 145)

The method according to claim 145, wherein the subject is resistant or intolerant to at least two prior tyrosine-kinase inhibitors.

### Claim 147 (depends on 144)

The method according to claim 144, wherein the leukemia results from a mutation in the Bcr-Abl kinase domain.

### Claim 148 (depends on 144)

The method according to claim 144, wherein the pharmaceutical composition comprises crystalline Form A of ponatinib hydrochloride.

### Claim 149 (depends on 144)

The method according to claim 144, wherein the pharmaceutical composition consists essentially of crystalline Form A of ponatinib hydrochloride.
